CS-3150
Phase 3Small molecule
Daiichi SankyoCS-3150 is one of 103 small molecule programs targeting Albuminuria. It is currently in Phase 3.
5
Indications
11
Total Trials
0
Active Trials
102
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1CS-3150
Daiichi SankyoPhase 3
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension3 trials
Renal Impairment2 trials
Efficacy and Safety1 trial
TED1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CS-3150. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company